Tirofiban: an investigational plateletglycoprotein IIb/IIIa receptor antagonist

Bibliography

• FUSTER V, BADIMON L, BADIMON JJ et al: The pathogene- sis of coronary artery disease and the acute coronary syndromes (1). New Engl. J. Med. (1992) 326:242–250.
   PubMed Web of Science ®Google Scholar
• FUSTER V, BADIMON L, BADIMON JJ et al: The pathogene-sis of coronary artery disease and the acute coronary syndromes (2). New Engl. J. Med. (1992) 326:310–318.
   PubMed Web of Science ®Google Scholar
• COLLER BS: Platelets in cardiovascular thrombosis andthrombolysis. In: The Heart and Cardiovascular System. Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE (Eds.), Raven Press, New York (1992):219–273.
   Google Scholar
• LEFKOVIT SJ, PLOW EF, TOPOL EJ: Platelet glycoproteinIlb/IIIa receptors in cardiovascular medicine. New Engl. J. Med. (1995) 332:1553–1559.
   PubMed Web of Science ®Google Scholar
• FARRELL DH, THIAGARAJAN P: Binding of recombinantfibrinogen mutants to platelets. J. Biol. Chem. (1984) 269:226–231.
   Google Scholar
• ANTIPLATELET TRIALISTS' COLLABORATION: Collabora-tive overview of randomised trials of antiplatelet ther-apy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. (1994) 308:81–106.
   PubMed Web of Science ®Google Scholar
• ANTIPLATELET TRIALISTS' COLLABORATION: Collabora-tive overview of randomised trials of antiplatelet ther-apy II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br. Med. J. (1994) 308:159–168.
   PubMed Web of Science ®Google Scholar
• PATRONO C: Aspirin as an antiplatelet drug. New Engl. J. Med. (1994) 330:1287–1294.
   PubMed Web of Science ®Google Scholar
• WEISS HJ, ALEDORT LM, KOCHWA S: The effect of salicy-lates on the hemostatic properties of platelets in man. J. Clin. Invest. (1968) 47:2169–2180.
   PubMed Web of Science ®Google Scholar
• ZUCKER MB, PETERSON J: Inhibition of adenosinediphosphate induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proc. Soc. Exp. Biol. Med. (1968) 127:547–551.
   PubMed Web of Science ®Google Scholar
• BENNETT JS, HOXIE JA, LEITMAN SF et al.: Inhibition offibrinogen binding to stimulated human platelets by a monoclonal antibody. Proc. Natl. Acad. Sci. USA (1983) 80:2417–2421.
   PubMed Web of Science ®Google Scholar
• PIDARD D, MONTGOMERY RR, BENNETT JS et al: Inter-action of AP-2, a monoclonal antibody complex, with intact platelets. J. Biol. Chem. (1983) 258:12582.
   PubMed Web of Science ®Google Scholar
• HYNES RO: Integrins: a family of cell surface receptors.Cell (1987) 48:549–554.
   PubMed Web of Science ®Google Scholar
• PONCZ M, EISMAN R, HEINDENREICH R et al.: Structureof the platelet membrane glycoprotein M./ Biol. Chem. (1987) 262:8476–8482.
   PubMed Web of Science ®Google Scholar
• PYTELA R, PIERSCHBACHER MD, GINSBERG MH et al:Platelet membrane glycoprotein MAIM: member of a family of Arg-Gly-Asp-specific adhesion receptors. Sci-ence (1986) 231:1559–1562.
   PubMed Web of Science ®Google Scholar
• KLOCZEWIAK M, TIMMONS S, LUKAS TJ et al.: Platelet receptor recognition site on human fibrinogen. Synthe-sis and structure-function relationship of peptides cor-responding to the carboxy-terminal segment of the gamma chain. Biochemistry (1984) 23:1767–1774.
   Google Scholar
• KLOCZEWIAK M, TIMMONS S, HAWIGER J: Recognition site for the platelet receptor recognition site on human fibrinogen and is not involved in the fibrin polymeri-zation reaction. Thromb. Res. (1983) 29:249–255.
   PubMed Web of Science ®Google Scholar
• COLLER BS, FOLTS JD, SMITH SR et al.: Abolition of in vivoplatelet thrombus formation in primates with mono-clonal antibodies to the platelet GPIIb/IIIa receptor: correlation with bleeding time, platelet aggregation and blockade of GPIIb/IIIa receptors. Circulation (1989) 80:1766–1774.
   PubMed Web of Science ®Google Scholar
• CAEN JP, CASTALDI PA, LECLERC JC et al.: Congenitalbleeding disorders with long bleeding time and normal platelet count, I: Glanzmann's thrombasthenia. Am. J. Med. (1966) 41:4–26.
   Web of Science ®Google Scholar
• COLLER BS, PEERSCHKE El, SCUDDER LE et al: A murinemonoclonal antibody that completely blocks the bind-ing of fibrinogen to platelets produces a thrombas-thenic-like state in normal platelets and binds to glycoprotein lib and or lila. j Clin. Invest. (1983) 72:325–328.
   PubMed Web of Science ®Google Scholar
• COLLER BS: Blockade of platelet GPIIb/IIIa receptors asan antithrombotic strategy. Circulation (1995) 92:2373–2380.
   PubMed Web of Science ®Google Scholar
• EPIC INVESTIGATORS: Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIa recep-tor in high-risk coronary angioplasty. The EPIC inves-tigation. New Engl. J. Med. (1994) 330:956–961.
   PubMed Web of Science ®Google Scholar
• DENNIS MS, HENZEL WJ, PITTI RM et al.: Platelet glyco-protein Ilb/IIIa protein antagonists from snake ven-oms: evidence for a family of platelet-aggregation inhibitors. Proc. Natl. Acad. Sci. USA (1990) 87:2471–2475.
   PubMed Web of Science ®Google Scholar
• SCARBOROUGH RM, ROSE JW, NAUGHTON MA et al.:Characterization of the integrin specificities of disinte-grins isolated from American pit viper venoms. J. Biol. Chem. (1993) 268:1058–1065.
   PubMed Web of Science ®Google Scholar
• SCARBOROUGH RM, NAUGHTON MA, TENG W et al.:Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycopro-tein IIb/IIIa. J. Biol. Chem. (1993) 268:1066–1073.
   Google Scholar
• PEERLINCK K, DE LEPELEIRE I, GOLDGERG M et al.: MK-383 (L-700,462), a selective non-peptide platelet glycoprotein IIb/IIIa antagonist is active in man. Circu-lation (1993) 88(4):1512–1517.
   PubMed Web of Science ®Google Scholar
• HARTMAN GD: Tirofiban hydrochloride platelet anti-ag-gregatory GPIIb/IIIa receptor antagonist. Drugs Future (1995) 20:897–901.
   Google Scholar
• GOULD RJ, CHANG CTC, LYNCH RJ et al. MK-0383 is a potent non-peptide mimic of RGD that inhibits glyco- protein 11b/Illa [abstract]. Thromb. Haemostasis (1993) 69:976.
   Google Scholar
• BARRETT JS, MURPHY G, PEERLINCK K etal: Pharmacok-inetics and pharmacodynamics of MK- 383, a selective non-peptide platelet glycoprotein-Ilb/Illa receptor an-tagonist, in healthy men. Clin. Pharmacol. Ther. (1994) 56:377–388.
   PubMed Web of Science ®Google Scholar
• PEERLINCK K, ARNOUT J, DE LEPELEIRE I etaL: Combinedeffect of aspirin and MK-383 (L-700,462), a selective GPM3/Illa antagonist in healthy volunteers. ihromb. Haemostasis (1993) 69(6):560.
   Web of Science ®Google Scholar
• THE EPILOG INVESTIGATORS: Platelet glycoproteinlibillla receptor blockade and low dose heparin during percutaneous coronary revascularization. New Engl. J. Med. (1997) 336(24):1689–1696.
   PubMed Web of Science ®Google Scholar
• THE CAPTURE INVESTIGATORS: Randomised placebo-controlled trial of abciximab before and during coro-nary intervention in refractory unstable angina: the CAPTURE study. Lancet (1997) 349:1429–1435.
   PubMed Web of Science ®Google Scholar
• KEREIAKES DJ, KLEIMAN NS, AMBROSE J et al.: Random-ized double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet Ilb/IIIa blockade in high-risk patients undergoing coronary angioplasty. JACC (1996) 26:536–542.
   Google Scholar
• THEROUX P, KOUZ S, ROY L et al.: Platelet membrane receptor glycoprotein lth/Illa antagonism in unstable angina. Circulation (1996) 94(6)899–905.
   Google Scholar
• THE RESTORE INVESTIGATORS: The effects of platelet glycoprotein Ilb/IIIa blockade with tirofiban on ad-verse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation (1997). In press.
   Google Scholar